Costa PT, McCrae RR, Dembroski TM: Agreeableness vs Antagonism: Explication of a Potential Risk Factor for CHD. In Siegman A, Dembroski T (Eds), In Search of Coronary-Prone Behavior. Hillsdale, NJ: Lawrence Erlbaum, 1989.
Dembroski TM, Costa PT Jr Coronary prone behavior: components of the type A pattern and hostility. J Pers. 1987 Jun;55(2):211-35.
Dembroski TM, MacDougall JM, Costa PT Jr, Grandits GA Components of hostility as predictors of sudden death and myocardial infarction in the Multiple Risk Factor Intervention Trial. Psychosom Med. 1989 Sep-Oct;51(5):514-22.
Dembroski TM, MacDougall JM, Lushene R Interpersonal interaction and cardiovascular response in type A subjects and coronary patients. J Human Stress. 1979 Dec;5(4):28-36.
Dembroski TM, MacDougall JM, Musante L Desirability of control versus locus of control: relationship to paralinguistics in the type A interview. Health Psychol. 1984;3(1):15-26.
Dembroski TM, Wiliams RB Assessment of Coronary-Prone Behavior. In: Schneidermann, et al (Eds), Handbook of Research Methods in Cardiovascular Behavioral Medicine. New York: Plenum Press, 1989
Dembroski TM Exercise hypertension: behavior and the dynamic action of risk factors. Herz. 1987 Apr;12(2):134-40.
MacDougall JM, Dembroski TM, Krantz DS Effects of types of challenge on pressor and heart rate responses in type A and B women. Psychophysiology. 1981 Jan;18(1):1-9.
MacDougall JM, Dembroski TM, Musante L The structured interview and questionnaire methods of assessing coronary-prone behavior in male and female college students. J Behav Med. 1979 Mar;2(1):71-83.
Matthews KA, Krantz DS, Dembroski TM, MacDougall JM Unique and common variance in structured interview and Jenkins Activity Survey measures of the type A behavior pattern. J Pers Soc Psychol. 1982 Feb;42(2):303-13.
Siegman AW, Boyle S Voices of fear and anxiety and sadness and depression: the effects of speech rate and loudness on fear and anxiety and sadness and depression. J Abnorm Psychol. 1993 Aug;102(3):430-7.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
